Fig. 1From: A novel nanobody as therapeutics target for EGFR-positive colorectal cancer therapy: exploring the effects of the nanobody on SW480 cells using proteomics approachCell viability of gefitinib and R9VH36 treatments in the SW480 cells. The cells were treated with various concentrations of the nanobodies (A) and gefitinib (B) for 3 days. The results are expressed as mean ± SD of triplicate experimentsBack to article page